EGFR and non-small cell lung carcinoma: A review evaluating clinical outcomes in NSCLC patients with uncommon EGFR mutations found an ORR of 60.6% for the Afatinib group, slightly higher than 50.3% for the Osimertinib group, although the difference was not statistically significant (64).